Phase I/II study of gemcitabine and epirubicine in stage IIIB-IV non small cell lung cancer

Frontiers in Bioscience

Volumn 11, Issue SUPPL. 1, 2006, Pages 2349-2353

  Illiano, Alfonso ^a   Battiloro, Ciro ^a   Formato, Roberta ^a   Danilo, Rocco ^a   Tortoriello, Anna ^a   Caponigro, Francesco ^a   Iaffaioli, Rosario Vincenzo ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NONE   (Italy)

Author keywords

Cancer; Epirubicine; Gemcitabine; Lung; Neoplasia; NSCLC; Small cell; Therapeutics; Treatment; Tumor

Indexed keywords

EID: 33744728329     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1974     Document Type: Article

References (22)

1. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327, 1434-1441 (1992)
2. Grilli R, AD Oxman & LA Julian: Chemotherapy for advanced non-small cell lung cancer: How much benefit a enough? J Clin Oncol 11, 1866-1872 (1993)
3. Souquet PI, E Chauvin & JP, Buissel: Polychemotherapy in advanced non small cell lung cancer: A meta-analysis. Lancet 342, 19-21, (1993)
4. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials-Non Small Cell Lung Cancer Collaborative Group. BMJ 311, 899-909 (1995)
5. Gatzemeier U, M. Heckmayr, DK Hossfeld, E Kaukel, G Koschel & R Neuhauss: A randomized trial with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cell lung cancer. Am J Clin Oncol 14, 405-411 (1991)
6. Gridelli C, F Perrone, S Palmeri, M D'Aprile, F Cognetti, A Rossi, V Gebbia, R Pepe, E Veltri, G Airoma, A Russo, P Incoronato, AF Scinto, G Palazzolo, M Natali, V Leonardi, C Gallo, S De Placido & AR Bianco: Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: a phase III multicentre randomised trial. The 'Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.). Ann Oncol 1, 821-826 (1996)
7. Georgoulias V, E Papadakis, A Alexopoulos, X Tsiafaki, A Rapti, M Veslemes, P Palamidas & I Vlachonikolis: Platinum-based and nonplatinum- based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357, 1478-1484 (2001)
8. Kosmidis P, N Mylonakis, C, Nicolaides, C Kalophonos, E Samantas, J Boukovinas, G Fountzilas, D Skarlos, T Economopoulos, D Tsavdaridis, P Papakostas, C Bacoyiannis & M Dimopoulos: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 20, 3578- 3585 (2002)
9. Sculier JP, JJ Lafitte, J Lecomte, T Berghmans, J Thiriaux, MC Florin, A Efremidis, CG Alexopoulos, P Recloux, V Ninane, P Mommen, M Paesmans & J Klastersky: A comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 13, 874-882 (2002)
10. Heinemann V, LW Hertel & GB Grindey: Comparison of the cellular pharmacokinetics and toxicity of 2′ .2′ -diflluorodeoxycytidine and 1 - Darabinofuranosylcytosine. Cancer Res 48, 4024-4031 (1988)
11. Anderson FI, B Lund & Back: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 12, 1 1-1826 (1994)
12. Abratt RE, WR Bezwoda & G Falkson: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12, 1535-1540 (1994)
13. Gatzemeier U, FA Shepherd & T Le Chevalier: Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 32A, 243-248 (1996)
14. Wils J, I Utama, L Sala, J, Smeets & A Riva: Phase II study of high-dose epirubicin in non-small cell lung cancer. Eur J Cancer 26, 1140-1141 (1990)
15. Feld R, R Wierzbicki, PL Walde, FA Shepherd, WK Evans, S Gupta, P Shannon & M Lassus: Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer. J Clin Oncol 10, 297-303 (1992)
16. Smit EF, HH Berendsen, DA Piers, J Smeets, A Riva & PE Postmus: A phase II study of high dose epirubicin in unresectable non small cell lung cancer. Br J Cancer 65, 405-408(1992)
17. Van Putten JWG, P Eppinga, Z Erjavec, GPJ De Leede, J, Nabers, JB Smeets, SD Th & HJM Groen: Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study. Br J Cancer 82, 806-811 (2000)
18. Klastersky JP, J Soulier & P Ravez: A randomized study comparing a high and standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 4:1780 (1986)
19. Gandara DR, J Crowley & RB Livingston: Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. J Clin Oncol 11:873 (1993)
20. Alberola V, C Camps & M Provencia: Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer (NSCLC): Results of a Spanish Lung Cancer Group phase III Trial (GEPC/98-02). Proc Am Soc Clin Oncol 20:308°(2001)
21. Edelman MJ, JI Clark & K Chansky: Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): Carboplatin/gemcitabine (CARB/G) followed by paclitaxel (P) or cisplatin/vinorelbine (C/V) followed by docetaxel (D). Proc Am Soc Clin Oncol 20:314a (2001)
22. Wachters FM, JW Van Putten, H Kramer, Z Erjavec, P Eppinga, JH Strijbos, GP de Leede, HM Boezen, EG de Vries & HJ Groen. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. Br J Cancer 89(7), 1192-9 (2003).